This is the first report suggesting a causal relationship between acute respiratory distress syndrome and 
Hericium erinaceum extract, which is commercialized as a diet food. A 63-year-old man was admitted to our hospital for intensive care of severe acute respiratory failure with diffuse infiltration in both lungs. Bronchoalveolar lavage fluid revealed a high percentage of lymphocytes. Lymphocyte stimulation test showed a strong reactivity against extract formulation of Hericium erinaceum (Yamabushitake), which he had taken four months before onset. He recovered with successful steroid pulse therapy under mechanical ventilation.
Concentrations of surfactant protein (SP)-A and SP-D in sera reflected the clinical features.
Introduction
Recent reports (1, 2) have demonstrated a consequence of lung injury induced by diet foods and crude drugs of plant origin. This disorder occurs in part by excessive activation of the immune host defense system, which is a beneficial effect of crude drugs such as . Many sorts of diet foods of plant origin are on the market, and some of them seem to include elements having similar effects as the herbal drug. We present here a probable case of acute respiratory distress syndrome (ARDS) caused by taking a diet food made from the extract of Hericium erinaceum [the Japanese name: Yamabushitake ( Fig. 1) 110 ng/ml), and KL-6 of 296 U/ml (cutoff: 500 U/ml). His chest roentgenogram on admission showed extensive ground-glass attenuation and air-space consolidation in both lung fields (Fig. 2) . Chest CT showed extensive ground glass attenuation and a small area of alveolar opacity predominantly in the inner and middle zone of both lungs and small bilateral pleural effusions (Fig. 3) . However, his electrocardiogram and ultrasonic cardiogram did not suggest left cardiac failure.
Central venous pressure was 3.0 cmH20. PaO2/ FiO2 at the initiation of PEEP was 67.7 Torr. These findings filled a criteria of ARDS proposed by Bernard G and coworkers (4). Therefore, we suspected he suffered from ARDS, which was caused by taking dry powder of extract of Hericium erinaceum every day approximately four months before onset.
He discontinued taking the diet food since the admission day.
Analyses of bronchoalveolar lavage (BAL) fluid on March 13
showed an increased cell count, high percentage of On March 10, we started to give him methylprednisolone of 1,000 mg/day and ulinastatin of 300,000 U/day with electrolytic fluid. He was weaned from the ventilator on March 14, and his condition was completely recovered at the time of discharge on April 17. Concentrations of SP-A and SP-D in serum were the highest on day 1, the second day after the start of steroid treatment, and their following decline precisely reflected his clinical improvement, which was estimated by chest X-ray, blood gas analysis, LDH and CRP (Table 2 ). In contrast, concentrations of KL-6 did not show significant increase during the follow-up days. a reasonable temporal sequence after the drug, (ii) followed a recognized response to the suspected drug, (iii) was confirmed by improvement on withdrawing the drug, and (iv) could not be reasonably explained by the known characteristics of the patient's clinical state. However, we could not assess finally whether this case was 'definite' due to a lack of a reexposure test, by which life-threatening reactions might be provoked. To our knowledge, this case is a first, although probable, report of acute lung injury associated with taking the extract of Hericium erinaceum, which is an edible mushroom classified into Basidiomycetes, Aphyllophorales, Hydna-ceae, and grows wild all over China and Japan. Recently, it has been on the market in Japan owing to an improvement of the method of cultivation.
The extract of Hericium erinaceum has been used as an herbal medicine in China for a long time. In Japan, some commodities made f rom the extract have been sold as a diet food. A recent report (6) showed that "erinacines H", a component of the cultured mycelia of Hericium erinaceum, promotes the synthesis of nerve growth factor (NGF), an activator of differentiation of immune cells. This report demonstrates that Hericium erinaceum has a biological ability as an immunomodulator. It is also known that alveolar macrophages are one source of NGF production, and this factor has potential to differentiate immature lymphocytes to helper T cells (7). The present patient revealed ARDS after 4-months of ingestion of extract of Y Hericium erinaceum, and helper T cells (CD4) in his BAL fluid were increased in number. Finally, lymphocyte stimulation test using this extract showed a significantly positive reaction. These observable facts demonstrate the causal relationship between the onset of ARDS and the extract. Another report showed Hericium erinaceum-induced occupational contact dermatitis (8). In general, drug-induced pulmonary disease is characterized by having a wide range of pathologic findings including chronic interstitial pneumonia (CIP), diffuse alveolar damage (DAD), bronchiolitis obliterans organizing pneumonia (BOOP) and eosinophilic pneumonia (EP) (16, 17). We could not assess the pathologic changes the present patient had, since we did not perform lung biopsy under the condition of severe respiratory failure. It is possible to deny, at least, CIP due to the rapid onset and EP by his BAL findings. The good response to steroid therapy seems to be compatible w ith BOOP rather than with DAD.
Many diet foods have appeared on the market, due to a rise in general concern to prevent chronic diseases such as arteriosclerosis and diabetes mellitus.
In consideration of such a social background, clinicians always should take notice of dietary habits of patients as a cause of lung injury.
In summary, this is a probable case of Hericium erinaceum extract-associated ARDS, and the new possibilities of serum markers, SP-A and SP-D are suggested for monitoring of the clinical course. 
